Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-25T05:48:43.925Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Trial of “Stelazine” on Apathetic Chronic Schizophrenics

Published online by Cambridge University Press:  08 February 2018

T. E. Weckowicz  and
T. F. Ward
T. E. Weckowicz
Affiliation:
The Saskatchewan Hospital, Weyburn, Sask., Canada
T. F. Ward
Affiliation:
The Saskatchewan Hospital, Weyburn, Sask., Canada
Get access Rights & Permissions [Opens in a new window]

Extract

“Stelazine” is the trademark name for Trifluoperazine. It is a derivative of phenothiazine with the following chemical formula: 10-3-(1-methyl-4-piperazinyl)-propyl-2-trifluoromethylphenothiazine dihydrochloride, or structurally:

Type
Original Articles
Information
Journal of Mental Science , Volume 106 , Issue 444 , July 1960 , pp. 1008 - 1015
Copyright
Copyright © Royal College of Psychiatrists, 1960 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Blewett, D. B., and Stefaniuk, W. B., “Weyburn Assessment Scale”, J. Ment. Sci., 1958, 104, 435.Google Scholar
2 Brooks, G. W., “Definitive Ataractic Therapy in the Rehabilitation of Chronic Schizophrenic Patients: A Preliminary Report on the Use of Trifluoperazine”, in: Trifluoperazine: Clinical and Pharmacological Aspects, 1958. Philadelphia: Lea and Febiger.Google Scholar
3 Fedeschi, D. H., Spencer, J. N., Macko, E., Fedeschi, R. E., Leonard, C. A., McLean, R. A., Flanagan, T., Cook, L., Mattis, P. A., and Fellows, E. J., “Pharmacology of Trifluoperazine”, ibid. Google Scholar
4 Feldman, P. E., “Safety and Toxicity of Trifluoperazine”, ibid. Google Scholar
5 Freyhan, F. A., “Occurrence and Management of Extrapyramidal Syndromen in Psychiatric Treatment with Trifluoperazine”, ibid. Google Scholar
6 Forrester, M. E., “Disturbed Chronic Psychotic Patients: Pilot Trial of Stelazine”, Brit. Med. J., 1958, 90–91.Google Scholar
7 Goldman, D., “Clinical Experience with Trifluoperazine Treatment of Psychotic States”, ibid. Google Scholar
8 Harris, A., “Sensory Depravation and Schizophrenia”, J. Ment. Sci., 1959, 105, 438.Google Scholar
9 Karn, W. N., and Kasper, S., “Pharmacologically Induced Parkinson-like Signs as Index of Therapeutic Potential”, Dis. Nerv. System, 1959, 20, 119.Google Scholar
10 Lehmann, H. E., and Knight, D. H., “Psychophysiologic Testing with a New Phrenotropic Drug”, in: Trifluoperazine: Clinical and Pharmacological Aspects, 1958. Philadelphia: Lea and Febiger.Google Scholar
11 Madgwick, J. R., McNeil, Desmond L. M., Driver, Marie and Preston, G., “Stelazine (Trifluoperazine): A Preliminary Report on a Clinical Trial”, J. Ment. Sci., 1958, 104, 437.Google Scholar
12 Rudy, L. H., Rinaldi, F., Costa, E., Himwich, H. E., Tuteur, W., and Glatzer, J., “The Use of Trifluoperazine in Treatment of Acute and Chronic Psychotic Patients”, in: Trifluoperazine: Clinical and Pharmacological Aspects, 1958. Philadelphia: Lea and Febiger.Google Scholar
13 Weckowicz, T. E., and Blewett, D. B., “Size Constancy and Abstract Thinking in Schizophrenic Patients”, accepted for publication by J. Ment. Sci. Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.